Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
21. November 2024 09:00 ET
|
Bright Minds Biosciences
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG),...
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
04. November 2024 14:41 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release...
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
21. Oktober 2024 08:30 ET
|
Bright Minds Biosciences
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing...
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
18. Oktober 2024 06:50 ET
|
Bright Minds Biosciences
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
16. Oktober 2024 10:45 ET
|
Bright Minds Biosciences
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
03. Oktober 2024 09:00 ET
|
Bright Minds Biosciences
Bright Minds Biosciences Inc. (NASDAQ: DRUG) is excited to announce its participation in the upcoming scientific conferences
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
19. September 2024 10:00 ET
|
Bright Minds Biosciences
Bright Minds Biosciences will host the Key Opinion Leader event with leading experts in epilepsy research and treatment on September 25
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
08. August 2023 06:50 ET
|
Bright Minds Biosciences
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders...
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
20. Juli 2023 06:50 ET
|
Bright Minds Biosciences
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders...
Bright Minds Announces Effective Date of Share Consolidation
11. Juli 2023 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on...